TARSUS PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
TARSUS PHARMACEUTICALS, INC. (TARS) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.21% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-06-30 was 4.21%, a 3.69% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.84%, a 7.47% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-09-30 was 3.94%, a 5.06% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-06-30 was 4.06%, a 5.36% decline year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month |
|---|---|---|---|
| 2026-06-30 | 4.21% 10-Q · filed 2026-08-06 | 3.86% 10-Q · filed 2026-08-06 | |
| 2026-03-31 | 3.84% 10-Q · filed 2026-05-06 | ||
| 2025-09-30 | 3.94% 10-Q · filed 2025-11-04 | 4.12% 10-Q · filed 2025-11-04 | |
| 2025-06-30 | 4.06% 10-Q · filed 2026-08-06 | 4.14% 10-Q · filed 2026-08-06 | |
| 2025-03-31 | 4.15% 10-Q · filed 2026-05-06 | ||
| 2024-09-30 | 4.15% 10-Q · filed 2025-11-04 | 4.10% 10-Q · filed 2025-11-04 | |
| 2024-06-30 | 4.29% 10-Q · filed 2025-08-06 | 4.10% 10-Q · filed 2025-08-06 | |
| 2024-03-31 | 4.08% 10-Q · filed 2025-05-01 | ||
| 2023-09-30 | 4.28% 10-Q · filed 2024-11-13 | 4.07% 10-Q · filed 2024-11-13 | |
| 2023-06-30 | 3.64% 10-Q · filed 2024-08-08 | 4.05% 10-Q · filed 2024-08-08 | |
| 2023-03-31 | 4.20% 10-Q · filed 2024-05-08 | ||
| 2022-09-30 | 3.20% 10-Q · filed 2023-11-09 | 2.22% 10-Q · filed 2023-11-09 | |
| 2022-06-30 | 3.00% 10-Q · filed 2023-08-10 | 2.08% 10-Q · filed 2023-08-10 | |
| 2022-03-31 | 1.86% 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |